Table 1.
Baseline clinical characteristics of the PF group and the DP group
| Variable | PF group(N = 41) n% | DP group(N = 45) n% | P-value |
|---|---|---|---|
| Gender | |||
| Male | 29(70.7) | 31(68.9) | 0.853 |
| Female | 12(29.3) | 14(31.1) | |
| Age (years) | |||
| Median (range) | 59(45–69) | 58(40–73) | |
| < 60 | 25(61.0) | 27(60.0) | 0.926 |
| ≥ 60 | 16(39.0) | 18(40.0) | |
| KPS | |||
| 90 | 33(85.0) | 39(86.7) | 0.370 |
| 80 | 8(19.5) | 5(11.1) | |
| 70 | 0(0) | 1(2.2) | |
| BMI (kg/m²) | |||
| Median (range) | 21.5(15.7–30.8) | 21.3(17.1–27.5) | |
| < 18.5 | 6(14.6) | 4(8.9) | 0.508 |
| ≥ 18.5 | 35(85.4) | 41(91.1) | |
| CCI | |||
| 0 | 31(75.6) | 31(68.9) | 0.716 |
| 1 | 10(24.4) | 13(28.9) | |
| 3 | 0(0) | 1(2.2) | |
| Smoking index | |||
| 0 | 15(36.6) | 20(44.4) | 0.755 |
| > 0, ≤ 400 | 10(24.4) | 10(22.2) | |
| > 400 | 16(39.0) | 15(33.3) | |
| Drinking | |||
| No | 28(68.3) | 30(66.7) | 0.872 |
| Yes | 13(31.7) | 15(33.3) | |
| Tumour location | |||
| Cervical | 7(17.1) | 5(11.1) | 0.729 |
| Upper thoracic | 13(31.7) | 19(42.2) | |
| Middle thoracic | 16(39.0) | 15(33.3) | |
| Lower thoracic | 3(7.3) | 2(4.4) | |
| Multiple primary | 2(4.9) | 4(8.9) | |
| Tumour length (mm) | |||
| Median (range) | 55(10–150) | 47(20–96) | |
| T stage* | |||
| T1 | 1(2.4) | 0(0) | 0.191 |
| T2 | 4(9.8) | 10(22.2) | |
| T3 | 25(61.0) | 28(62.2) | |
| T4 | 11(26.8) | 7(15.6) | |
| N stage* | |||
| N0 | 2(4.9) | 3(6.7) | 1.000 |
| N1 | 39(95.1) | 42(93.3) | |
| M stage* | |||
| M0 | 30(73.2) | 30(66.7) | 0.512 |
| M1a | 11(26.8) | 15(33.3) | |
| TNM stage* | |||
| IIA, IIB | 4(9.8) | 9(20.0) | 0.236 |
| III | 26(63.4) | 21(46.7) | |
| IVA | 11(26.8) | 15(33.3) |
Abbreviations: BMI = body mass index; CCI = Charlson comorbidity index; KPS = Karnofsky performance status; PF = cisplatin + 5-Fu; DP = docetaxel + cisplatin; *TNM stage was assessed according to the 6th edition of the American Joint Commission on Cancer (AJCC) staging system